GIM
LAB icon

Granahan Investment Management’s Standard BioTools LAB Stock Holding History

Granahan Investment Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-472,970
Closed -$1.9M – 191
2020
Q2 		$1.9M Sell
472,970
-269,745
-36% -$939K 0.07% 156
2020
Q1 		$1.89M Buy
742,715
+56,971
+8% +$187K 0.1% 137
2019
Q4 		$2.39M Buy
685,744
+88,865
+15% +$313K 0.11% 133
2019
Q3 		$2.76M Sell
596,879
-138,509
-19% -$1.09M 0.15% 122
2019
Q2 		$9.06M Sell
735,388
-45,730
-6% -$582K 0.45% 63
2019
Q1 		$10.4M Buy
781,118
+219,426
+39% +$2.31M 0.56% 52
2018
Q4 		$4.84M Buy
+561,692
New +$4.38M 0.34% 83

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Granahan Investment Management's LAB Position: Q3 2020 in Review

Granahan Investment Management sold out of Standard BioTools (LAB) in Q3 2020, closing a stake of 472,970 shares — an estimated $1.9M sold.

Granahan Investment Management first reported a position in LAB in Q4 2018 and held it in 7 quarters. The position peaked at $10.4M in Q1 2019. 134 funds tracked by Wall St. Rank hold LAB as of Q3 2020.

  • Granahan Investment Management reported no remaining Standard BioTools position as of Q3 2020 after selling out during the quarter.
  • Granahan Investment Management sold 472,970 Standard BioTools shares in Q3 2020, an estimated $1.9M.
  • Granahan Investment Management first reported a position in Standard BioTools in Q4 2018 and held it in 7 quarters.
  • Granahan Investment Management's Standard BioTools position peaked at $10.4M in Q1 2019.
  • 134 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2020.

Based on Granahan Investment Management's 13F filing for Q3 2020, filed 12 Nov 2020.